David J. FitzGerald

Area of research

Immunology · Biotechnology

Research interest

Research interests include Toxin Mechanisms and Immunotoxins, Transgenic Plants and Applications, Monoclonal and Polyclonal Antibodies Research, and Bacteriophages and microbial interactions.

h-index

citations

7,361

works

105

NIH funding

—

primary concept

—

✉ Find email ↗

Recent publications

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Blood 2018cited by 70position: middledoi

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

Journal of Clinical Oncology 2012cited by 296position: middledoi

Grants

A Pre-College Instructional Improvement Implementation Project

NSF7502202$54,9661975–1976PIRePORTER

An Implementation Project in Elementary School Science

NSF7407209$21,2481974–1975PIRePORTER

Frequent collaborators

Martin S. Tallman · Midwestern University2 papers (2012–2018)Steven Coutré · Stanford University2 papers (2012–2018)Robert J. Kreitman · National Cancer Institute2 papers (2012–2018)Wyndham H. Wilson · National Institutes of Health2 papers (2012–2018)Ira Pastan · Center for Cancer Research2 papers (2012–2018)Maryalice Stetler‐Stevenson · National Cancer Institute2 papers (2012–2018)Tadeusz Robak · Medical University of Lodz2 papers (2012–2018)Robert J. Lechleider · MacroGenics (United States)1 papers (2012–2012)Mark C. Lanasa · AstraZeneca (United States)1 papers (2018–2018)Guozhi Gao · Amgen (United States)1 papers (2018–2018)— · 1 papers (2018–2018)